fashion -WSS

fashion

author：comprehensive 2025-10-01 21:48:39 - browse：11222

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Scrutiny of post

focus

Wikipedia

WSS

UnitedHealth argues against case alleging wrongful AI care denials

UnitedHealth argues against case alleging wrongful AI care denials

Cue Health, Covid

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Christmas in the PICU brings some surprising joy

Christmas in the PICU brings some surprising joy

leisure time

fashion

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

SEC charges former device maker CEO with $41 million fraud

Trump demands the U.S. pay no more for drugs than other countries … again

Eyeing GLP

At least 13 dead in Texas as scorching temps continue

Hospitals owned by private equity see complications spike 25%

Medical records are filled with copy

Fentanyl is making it harder to start addiction treatment

How one medical school became remarkably diverse

What STAT readers think about the FDA and patient advocacy

focus

Editas, Vertex strike deal on CRISPR

Making the case for fair compensation in clinical trials

How to keep neuroscience’s past racism from being its future

How to keep neuroscience’s past racism from being its future

Cue Health, Covid

Digital health: a case of mistaken identity

leisure time

focus

Wikipedia

hotspot